Oliver Fetzer has served as Chief Executive Officer (CEO) and Board Member of Viridos since November 2014. Previously, Oliver served for five years as President and CEO of Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics. Under Oliver’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly-traded clinical development stage company with a pipeline of product candidates.
Prior to Cerulean Pharma, Oliver served for five years in a range of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Corporate Development and Research & Development.
Oliver began his career at Boston Consulting Group (BCG), a global management consulting firm, where he advanced over nine years from consultant to Project Leader, Principal, and ultimately, Partner and Managing Director. He has served on the board of Tecan Group AG since 2011. He served on the boards of Arena Pharmaceuticals, Inc. from 2017 to 2022, Cerulean Pharma, Inc. from 2009 to 2014, and Auxilium Pharmaceuticals, Inc. from 2005 to 2015.
Oliver received a B.S. in Biochemistry from the College of Charleston, a Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.